

Claims 1-7 (cancelled)

Claim 8 has been currently amended to read: A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of:

producing an AT₄ receptor antagonist ligand with the structure NH₃⁺-
norleucine-tyrosine-isoleucine-histidine-COO⁻, norleucine-tyrosine-
isoleucine-(6-amino-hexanoic acid)-CONH₂, or norleucine-tyrosine-leucine-
Ψ-(CH₂-HN₂)³⁻⁴-histidine-proline-phenylalanine)-COO⁻, and
administering the AT₄ receptor antagonist ligand.

Claim 9. (currently amended) The method of inhibiting angiogenesis accordingly to claim 8, further comprising the delivery of the AT₄ receptor antagonist ligand locally.

Claim 10. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist ligand intravascularly.

Claim 11. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist ligand intramuscularly.

Claim 12. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist ligand intraperitoneally.

Claim 13. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist ligand subcutaneously.

Claim 14. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT₄ receptor antagonist ligand orally.

Claim 15 has been currently amended to read: A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of:

producing an AT₄ receptor antagonist ligand with the structure NH₃⁺-norleucine-tyrosine-isoleucine-histidine-COO⁻, norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH₂, or norleucine-tyrosine-leucine-Ψ-(CH₂-HN₂)³⁻⁴-histidine-proline-phenylalanine)-COO⁻, and
administering the AT₄ receptor antagonist ligand.

Claim 16. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising delivery of the AT₄ receptor antagonist ligand locally.

Claim 17. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the delivery of the AT₄ receptor antagonist ligand intravascularly.

Claim 18. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the delivery of the AT₄ receptor antagonist ligand intramuscularly.

Claim 19. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the delivery of the AT₄ receptor antagonist ligand intraperitoneally.

Claim 20. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the step of applying the AT₄ receptor antagonist ligand subcutaneously.

Claim 21. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the step of applying the AT₄ receptor antagonist ligand orally.

Claim 22 has been currently amended to read: A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of:

producing an AT₄ receptor antagonist ligand with the structure NH₃⁺-norleucine-tyrosine-isoleucine-histidine-COO⁻, norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH₂, or norleucine-tyrosine-leucine-Ψ-(CH₂-HN₂)³⁻⁴-histidine-proline-phenylalanine)-COO⁻, and

administering the AT₄ receptor antagonist ligand.

Claim 23. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist ligand locally to the tumor.

Claim 24. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist ligand intravascularly.

Claim 25. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist ligand intramuscularly.

Claim 26. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist ligand intraperitoneally.